NCT02623946View on ClinicalTrials.gov

Motor Evoked Potentials as a Biomarker in Alemtuzumab Treated Multiple Sclerosis Patients

CompletedOBSERVATIONAL
Enrollment

10

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

December 9, 2020

Study Completion Date

February 28, 2021

Conditions
Multiple Sclerosis
Trial Locations (1)

J8Y 1W2

Clinique Neuro-Outaouais, Gatineau

All Listed Sponsors
collaborator

CogState Ltd.

INDUSTRY

lead

Clinique Neuro-Outaouais

OTHER

NCT02623946 - Motor Evoked Potentials as a Biomarker in Alemtuzumab Treated Multiple Sclerosis Patients | Biotech Hunter | Biotech Hunter